AON Joins Nasdaq to Further Patient-Centric Community Oncology Care
The American Oncology Network has started trading on Nasdaq with the goal of continuing the growth of the organization.
New Data From 2023 ESMO Congress Further Define the Evolving Role of ADCs in NSCLC
With a plethora of data coming out of the 2023 European Society for Medical Oncology Congress, findings from multiple clinical trials examining antibody-drug conjugates in non–small cell lung cancer demonstrated encouraging antitumor activity and manageable safety profiles, including results from the phase 3 TROPION-Lung01 study, which evaluated datopotamab deruxtecan vs docetaxel in pretreated patients with advanced or metastatic disease.
OSE2101 Cancer Vaccine Yields Favorable OS vs SOC in HLA-A*02+ ICI-Resistant NSCLC
Benjamin Besse, MD, PhD, discusses the results from the ATALANTE-1 trial and details the mechanism of action of the OSE2101 vaccine.
IO Combos Yield OS Advantage Vs Chemo Alone in Stage IV PD-L1–Negative NSCLC
As treatments for patients with stage IV non–small cell lung cancer continue to evolve, patients with PD-L1–negative disease represent a unique cohort and chemotherapy/immunotherapy or immunotherapy doublet regimens appear to be effective.
Considering the Data Behind Belzutifan's Approval in VHL Disease–Associated Cancers
Jaleh Fallah, MD, discusses the FDA's evaluation of data from the phase 2 LITESPARK-004 trial, which supported the approval of belzutifan in von Hippel-Lindau–associated cancers.
Markman Underscores Unanswered Questions in Ovarian Cancer Management
Although advancements were “simple” to track for more than 40 years and left few questions open for evaluation in the ovarian cancer treatment paradigm, new questions have begun to develop surrounding the complexity of care.
Lamanna Details Evolution of CLL Treatment Following Resistance
Nicole Lamanna, MD, discusses treatment options for patients with chronic lymphocytic leukemia who develop resistance to a prior treatment.
Investigators Deliver Updates on Evolving Clinical Trials Evaluating ADCs in Lung Cancer
Melissa L. Johnson, MD, Terufumi Kato, MD, and Pasi A. Jänne, MD, PhD, present updates from the International Association for the Study of Lung Cancer 2023 World Conference on Lung Cancer.
Novel B7-H4 Targeted ADCs Generate Activity and Show Manageable Safety Profile in Breast and Other Cancers
Two novel antibody-drug conjugates, HS-20089 and SGN-B7H4V, targeting the highly expressed immune checkpoint ligand B7-H4 have demonstrated manageable safety profiles and shown anti-tumor activity in first-in-human dose-escalation portions of phase 1 trials and will move forward to the next portions of the studies.
ImPrint Biomarker Predicts Immunotherapy Response in Patients With HR+/HER2– Breast Cancer
Denise M. Wolf, PhD, discusses the methods used to conduct the I-SPY2 study and the implications that immune biomarkers could have on selecting treatment for patients with hormone receptor–positive, HER2-negative breast cancer in the future.
Updated Data Continue to Aid IO-Based Frontline Treatment Decisions in Advanced RCC
Tian Zhang, MD, MHS, details how updated data presented at the 2023 ASCO Annual Meeting from trials such as KEYNOTE-426 and CLEAR have showed the sustained efficacy of VEGF plus immunotherapy combinations vs sunitinib in the first-line setting; discusses where the immunotherapy-only combination of ipilimumab and nivolumab fits in the frontline setting; and highlights how data from CONTACT-03 provided key insights on the use of immunotherapy in patients with advanced renal cell carcinoma after progression on a prior immune checkpoint inhibitor.
Dato-DXd Significantly Improves PFS in Select Subsets of Advanced/Metastatic NSCLC
The Trop-2 directed antibody drug conjugate datopotamab deruxtecan demonstrated a statistically significant improvement in progression-free survival vs docetaxel in patients with advanced or metastatic non–small cell lung cancer, however those with squamous histology did not experience a benefit.
Etigilimab Plus Nivolumab Shows Activity in Recurrent/Advanced Solid Tumors, and Possible Biomarkers Emerge
Combination treatment with etigilimab and nivolumab was well tolerated in patients with recurrent or advanced solid tumors and promising efficacy was seen for patients with PD-L1 low disease
Pembrolizumab Plus Chemoradiotherapy Shows Statistically Significant PFS Benefit vs SOC in High-Risk Locally Advanced Cervical Cancer
The addition of pembrolizumab to external beam radiotherapy and concurrent chemotherapy, followed by brachytherapy, resulted in statistically significant and clinically meaningful improvements in progression-free survival when compared with placebo plus EBRT/chemoradiotherapy/brachytherapy in patients with newly diagnosed, previously untreated, high-risk locally advanced cervical cancer.
Next-Generation Aniten Masofaniten Gains Momentum in mCRPC
The emergence of a novel class of compounds, known as anitens, potentially offers clinicians the ability to elongate responses for patients with metastatic castration-resistant prostate cancer, with the first-in-class N-terminal domain androgen receptor inhibitor masofaniten showing promise as it moves to the phase 2 portion of a phase 1/2 trial.
DLL3-Targeting Agents Are Poised to Fill Unmet Needs in SCLC
Expression of DLL3, an inhibitor ligand of the Notch pathway associated with tumorigenesis, has emerged as a target of interest for drug development.
Pirtobrutinib to be Compared with Ibrutinib in CLL/SLL Ongoing BRUIN CLL-314 Trial
The phase 3 BRUIN CLL-314 trial evaluating the selective noncovalent BTK inhibitor pirtobrutinib vs the potent covalent BTK inhibitor ibrutinib is currently enrolling patients with chronic lymphocytic leukemia and small lymphocytic lymphoma who previously received treatment with non-BTK inhibitor therapy.
Dual Inhibition With Bezuclastinib/Sunitinib Aims to Fill an Unmet Need in GIST
Combination therapy targeting multiple exons where mutations commonly develop in gastrointestinal stromal tumor may represent a promising treatment approach to increase efficacy when patients develop resistance to therapies such as imatinib.
Venetoclax/Carfilzomib/Dexamethasone Triplet Shows Early Efficacy in t(11;14)+ R/R Myeloma
The addition of venetoclax to carfilzomib and dexamethasone increased response rates compared with carfilzomib plus dexamethasone alone in patients with t(11:14)-positive relapsed/refractory multiple myeloma.
BASECAMP-1 Trial Selects Patients With Solid Tumors for Future Treatment With Novel CAR T-Cell Therapy
J. Randolph Hecht, MD, discusses the challenges researchers have faced in the development of cellular therapy for patients with solid tumors, and details how A2B530 could potentially overcome some of these obstacles.
Adagrasib Yields Durable Benefit for Patients With KRAS G12C–Mutant NSCLC
Adagrasib monotherapy provided durable efficacy for patients with KRAS G12C–mutated locally advanced or metastatic non–small cell lung cancer, according to 2-year follow-up data from the phase 1/2 KRYSTAL-1 trial.
Prognostic Model Could Help Predict Survival Outcomes for Patients With Myelofibrosis Undergoing AlloHCT
A predictive system developed using data from United States and European stem cell transplant registries was prognostic of survival in patients with myelofibrosis undergoing allogeneic hematopoietic cell transplantation.
Retrospective Study Associates Alprazolam With Improved PFS in Pancreatic Cancer
The benzodiazepines lorazepam and alprazolam had differing effects on progression-free survival (PFS) outcomes among patients with pancreatic cancer, with lorazepam demonstrating an association with decreased PFS and alprazolam prolonging PFS.
BI 764532 Yields Promising Safety and Efficacy Results in DLL3+ SCLC and Neuroendocrine Carcinomas
Martin Wermke, MD, discusses why the novel agent may serve as a promising treatment option targeting DLL3.
Subgroup Observations From Missed KEYNOTE-789 Data in NSCLC Provide Insight for the Future
James Chih-Hsin Yang, MD, PhD, discusses the implications of the phase 3 KEYNOTE-789 trial and what directions investigators can examine in the future to help fill the unmet need for patients with TKI-resistant, EGFR-mutated metastatic non–small cell lung cancer.
Atezolizumab Plus Chemotherapy Demonstrates Intracranial Activity in Advanced Nonsquamous NSCLC
Combination treatment with atezolizumab, carboplatin, and pemetrexed showed activity in patients with advanced nonsquamous non–small cell lung cancer and untreated brain metastases without neurologic symptoms or asymptomatic with medical treatment.
Perioperative Durvalumab Plus SOC Shows Promising EFS Results in Muscle-Invasive Urothelial Carcinoma
Treatment with neoadjuvant durvalumab plus gemcitabine and cisplatin followed by radical surgery and adjuvant durvalumab for patients with muscle-invasive urothelial carcinoma resulted in 2-year event-free survival rates that met the primary end point of the phase 2 SAKK 06/17 trial.
Early Data Signal Response With CBX-12 in Advanced or Metastatic Solid Tumors
Funda Meric-Bernstam, MD, discusses the safety of CBX-12 and exploring dosage of the agent.
Bazhenova Details Potential Pathways Forward for Targeting KRAS Mutations in NSCLC
Lyudmila A. Bazhenova, MD, discusses upcoming inhibitors of interest in the combination therapy space for patients with KRAS G12C–mutant NSCLC.
Komrokji Examines Differences Between the WHO and ICC MDS Criteria
Rami Komrokji, MD, discusses an international dataset analysis of the 2 current classification systems for patients with myelodysplastic syndromes, as well as the next steps being taken to develop a more harmonized classification system.
Dr Ganesan on the Use of ctDNA Assays For MRD Detection in Cancer Care
Dr Habib on Developments in Palliative Care For Patients With Cancer
Dr Boland on the Emergence of KRAS G12C Inhibitors in mCRC
Dr In on the Increased Incidence of Gastric Cancer in Minority Patient Populations
2 Clarke Drive Cranbury, NJ 08512